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BACKGROUND: The prognostic significance of isolated tumour cells (ITCs) in the sentinel nodes (SNs) is controversial in early breast
cancer, and some centres have abandoned immunohistochemistry to detect ITCs.
METHODS: Patients with unilateral pT1N0 breast cancer, operated between February 2001 and August 2005 at a university hospital
were included in this prospective, population-based cohort study. Survival of 936 patients with or without isolated tumour cells
(ITC) in their SNs were compared with the log-rank test and Cox regression analysis.
RESULTS: Eight hundred sixty one (92.0%) patients were ITC-negative (pN0i−) and 75 (8.0%) ITC-positive (pN0i+). Patients with ITC-
positive cancer received more frequently adjuvant systemic therapies than those with ITC-negative cancer. The median follow-up
time was 9.5 years. Ten-year distant disease-free survival was 95.3% in the pN0i− group and 88.8% in the pN0i+ group (P= 0.013).
ITCs were an independent prognostic factor in a Cox regression model (HR= 2.34, 95% CI 1.09–5.04; P= 0.029), together with
tumour Ki-67 proliferation index and diameter. ITCs were associated with unfavourable overall survival (P= 0.005) and breast
cancer-specific survival (P= 0.001).
CONCLUSIONS: We conclude that presence of ITCs in the SNs is an adverse prognostic factor in early small node-negative breast
cancer, and may be considered in the decision-making for adjuvant therapy.
British Journal of Cancer (2018) 118:1529–1535; https://doi.org/10.1038/s41416-018-0052-7
INTRODUCTION
The regional lymph node status has long been known to be an
important prognostic factor in early breast cancer.1 Preoperative
axillary ultrasound and a subsequent sentinel node biopsy (SNB)
are currently the standard of care in the staging of clinically node-
negative breast cancer. After harvesting, the sentinel nodes (SNs)
are evaluated with immunohistochemical (IHC) staining of several
tissue sections, which allows reasonably accurate assessment of
both isolated tumour cells (ITCs) and micrometastases, whereas
routine haematoxylin and eosin (H&E) staining often fails to detect
them.2
In 2002, the American Joint Committee on Cancer (AJCC) TNM-
classification (the 6th edition) defined and distinguished ITCs
(pN0i+) from micrometastases (pN1mi).3 Since the definition of
the ITCs their clinical importance has been debated, some arguing
ITCs to have true metastatic potential and prognostic importance,
while others consider them as artefacts from benign transporta-
tion after tumour manipulation, or otherwise of little importance
in prognostication.4–6 In the beginning of the SN era, even the
detection of small tumour deposits (including ITCs) in the lymph
nodes led to axillary lymph node dissection (ALND), but data from
clinical trials and other evidence now indicates that ALND does
not improve survival of patients with limited SN involvement.7–9
Consequently, several guidelines now recommend to stop looking
for ITCs, and many centres have abandoned IHC analysis of the
SNs altogether.9,10
Although it is evident that patients with only ITCs in their SNs
do not benefit from an ALND, the long-term prognostic
significance of ITCs and their impact on the decision-making
regarding the need of adjuvant therapy is unclear.10–15 To assess
the clinical significance of ITCs, we aimed to investigate in the
present study the long-term prognostic importance of ITCs in a




A total of 1865 patients who had not been treated with
neoadjuvant systemic therapy underwent breast surgery for
unilateral, invasive pT1 (the largest tumour diameter ≤ 2 cm)
breast cancer at the Breast Surgery Unit of the Comprehensive
Cancer Center of Helsinki University Hospital, Finland, between
February 2001 and August 2005, and were considered for this
prospective cohort study. Since the Breast Surgery Unit of the
Helsinki University Hospital is the only dedicated breast unit in a
defined geographical region encompassing the Helsinki metro-
politan area, serving a population of approximately 1.5 million,
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and operates close to 100% of all breast cancer patients in this
region, the current data are close of being population-based.
We excluded 929 (49.8%) patients from the cohort of 1865
patients for the reasons listed in Fig. 1, the most frequent reasons
being presence of SN micrometastasis or macrometastasis (n=
443), presence of bilateral breast cancer or history of contralateral
breast cancer (n= 190), ALND done without an SNB (n= 168), or
technically unsuccessful SNB (n= 60). Patients with ITCs in the SNs
after a SNB and with a micrometastasis or a macrometastasis in
the non-sentinel nodes after an ALND were also excluded from
the study population (n= 1). The patients who had an ALND
without a SN metastasis were excluded, since lymph nodes
removed at ALND are generally not as meticulously investigated
as the SNs, and ITCs are often missed. The remaining 936 patients
with unilateral pN0 cancer form the present study population. The
patients were categorised into two groups according to the SN
biopsy results, either ITC-negative (pN0i−; n= 861 [92.0%]) or ITC-
positive (pN0i+; n= 75 [8.0%]). The patient and tumour char-
acteristics are provided in Table 1.
The research protocol was approved by an Ethics Committee at
the Helsinki University Hospital.
Surgery
Preoperative lymphoscintigraphy preceded the SN biopsy, and the
SNs were identified at surgery using a gamma probe and blue dye
as described in detail elsewhere.16 Nineteen (2.2%) of the 861
patients with pN0i− underwent a level I-II ALND due to surgeon or
patient preference, and the majority of patients with pN0i+
underwent a level I-II ALND (62 [82.7%] out of 75, Table 2).
Histopathology
The breast and lymph node tissue specimens were sent to the
pathology laboratory separately as fresh unfixed specimens and
examined histologically by specialised breast pathologists. SNs
were sliced in multiple sections 1–1.5 mm apart. An intraoperative
frozen section analysis, including rapid IHC staining of the multiple
sections, was performed. Rest of the SN tissue was formalin fixed,
paraffin embedded and haematoxylin and eosin (H&E) stained in
two sections. If no metastases were found, or if ITCs or
micrometastasis was found in the SN frozen sections, an IHC
staining for cytokeratin was performed, in addition to routine H&E
staining. IHC staining was not done when a 2mm or larger
metastasis was found in frozen section analysis. The lymph nodes
from the axillary clearance specimen were examined after staining
with H&E. The histopathological analyses were performed in one
specialist pathology laboratory.17
Radiation therapy and adjuvant systemic therapy
Radiotherapy and systemic adjuvant treatments were adminis-
tered according to the institutional guidelines (Table 2). After
breast-conserving surgery, postoperative whole-breast radiother-
apy was generally given to a cumulative dose of 50 Gy in 25
fractions. Tangential whole breast radiation fields were used after
breast-conserving surgery. The target volume usually included the
lower axilla. Separate axillary or supraclavicular fields were not
used when the postsurgical axillary status was either pN0i− or
pN0i+. A booster dose of 10 to 16 Gy was given to premenopausal
women to the breast tumour site. Radiotherapy was not
administered after mastectomy in this patient population with
pT1 node-negative disease.
Adjuvant systemic treatment was administered depending on
the patient and disease characteristics. In general, adjuvant
systemic therapy was administered to patients considered to
have a moderate-to-high risk of recurrence. Presence of ITCs in the
SNs was not considered a mandatory indication for systemic
adjuvant therapy. Premenopausal women with oestrogen receptor
(ER) or progesterone receptor (PR)-positive cancer were scheduled
to receive tamoxifen for a time period of 5 years, and
postmenopausal women usually received an aromatase inhibitor
for 5 years. Patients <65 years of age with moderate-to-high risk
HER2-positive cancer received adjuvant trastuzumab and che-
motherapy after May 2005, and a few patients prior to this within
the context of a clinical trial.18
Follow-up
The median follow-up time was 9.5 (interquartile range [IQR] 2.1)
years after the date of primary breast surgery. In the subset of
patients with pN0i− and pN0i+ cancer the median follow-up time
was 9.5 (IQR 2.0) years and 9.0 (IQR 1.7) years, respectively. Regular
follow-up visits were planned at one, three, and 5 years after
pT1 invasive unilateral breast cancer
n= 1865
Excluded:
ALND due to unsuccesful SNB n= 60 
Direct ALND n= 168
No axillary surgery n= 2
Lost to follow-up n= 32
Patients included in the study
n= 936
pN0i– n= 861 pN0i+ n= 75
Died of myocardial infarction immediately after surgery n= 1
History of other malignancy n= 25
Distant metastases at presentation n= 7
Contralateral breast cancer n= 190
Sentinel node metastasis n= 443
ITC in sentinel node, micrometastasis in ALND specimen n= 1
Fig. 1 Patient inclusion flowchart
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breast surgery, and were organised at the Helsinki University
Hospital. These visits included physical examination, blood cell
counts, blood chemistry, and bilateral mammography. Breast and
axillary ultrasound, bone isotope scan, and computerised tomo-
graphy were performed whenever considered necessary. If
concern of breast cancer recurrence occurred, the patients had
access to further visits. After the first 5 years, the follow-up visits
took place at the local health care centres or at private health care
providers, according to patient preference. When cancer recurred,
the patients were referred to the Helsinki University Hospital for
further examinations and treatment. The date of breast cancer
recurrence, the cause of death, and the date of death were
extracted from the hospital records. In addition, data about cancer
survival were obtained from the Finnish Cancer Registry, which
has a coverage exceeding 95% in the population. Thirty-two
patients were lost follow-up.
Statistical methods
Frequency tables were analysed with the chi-squared test, and
continuous distributions were compared with the Mann-Whitney
U-test. Distant disease-free survival was calculated from the date
of breast surgery to the date of first occurrence of breast cancer
metastases outside of the locoregional region, censoring patients
alive without distant metastases on the date of the last patient
contact or on the date of death. Locoregional recurrence-free
survival time was calculated from the date of breast surgery to the
date of first regional lymph node or ipsilateral breast cancer
recurrence, censoring patients without locoregional recurrence on
the date of last follow-up contact or on the date of death. Breast
cancer-specific survival was calculated from the date of breast
surgery to the date of death considered to result from breast
cancer, censoring patients without such an event on the last date
of contact or on the date of death from an intercurrent cause.
Overall survival was calculated from the date of surgery to the
date of death from any cause, censoring patients who were alive
on the date of the last contact.
Life tables were analysed using the Kaplan-Meier method, and
survival between groups was compared with the log-rank test. A
Cox proportional hazards regression model was used to assess the
independent influence of covariables on survival. Variables with a
P-value less than 0.1 in the univariable survival analysis were
entered into a multivariable backward stepwise Cox regression
analysis. Two-sided P-values < 0.05 were considered statistically
Table 1. Patient and tumour characteristics stratified by the presence
of ITCs in the sentinel lymph nodes
Number of pN0i−
patients (%) (n= 861)
Number of pN0i+
patients (%) (n= 75)
P-value
Age at diagnosis (years)
Median 58 57 0.262
Range 27–92 35–87
Tumour size (mm)
Median 12 13 0.021
Range 1–20 1–20
Biopsy method
FNAC 439 (51.0) 37 (49.3) 0.788
CNB 374 (43.4) 33 (44.0)
Surgical
biopsy
42 (4.9) 5 (6.7)
NA 6 (0.7) 0 (0.0)
Tumour histology
Ductal 546 (63.4) 50 (66.7) 0.519
Lobular 155 (18.0) 15 (20.0)
Other 160(18.6) 10 (13.3)
Histological grade
I 340 (39.5) 25 (33.3) 0.262
II 359 (41.7) 39 (52.0)
III 151 (17.5) 11 (14.7)
NA 11 (1.3) 0 (0.0.)
Multifocality
Unifocal 769 (89.3) 64 (85.3) 0.291
Multifocal 92 (10.7) 11 (14.7)
Oestrogen receptor
Negative 96 (11.1) 8 (10.7) 0.888
Positive 761 (88.4) 67 (89.2)
NA 4 (0.5)
Progesterone receptor
Negative 267 (31.0) 19 (25.3) 0.286
Positive 587 (68.2) 56 (74.7)
NA 7 (0.8)
Ki-67 (MIB-1)
0–19% 539 (62.6) 48 (64.0) 0.746
20–30% 166 (19.3) 12 (16.0)
>30% 143 (16.6) 14 (18.7)
NA 13 (1.5) 1 (1.3)
HER-2 (CISH)
Negative 675 (78.4) 55 (73.3) 0.424
Positive 52 (6.0) 4 (5.3)
NA 134 (15.6) 16 (21.3)
ITC isolated tumour cell, FNAC fine needle aspiration cytology, CNB core
needle biopsy, HER-2 (CISH) human epidermal growth factor receptor 2
(chromogenic in situ hybridisation) NA not available





patients (%) (n= 75)
P-value
Breast surgery
Mastectomy 144 (16.7) 24 (32) <0.001
BCS 717 (83.3) 51 (68)
Axillary surgery
SNB 842 (97.8) 13 (17.3) <0.001
SNB and
ALND
19 (2.2) 62 (82.7)
Radiotherapy
No 150 (17.4) 20 (26.7) 0.040
Yes 710 (82.5) 54 (72.0)
NA 1 (0.1) 1 (1.3)
Endocrine therapy
No 480 (55.7) 16 (21.3) <0.001
Yes 377 (43.8) 58 (77.3)
NA 4 (0.5) 1 (1.4)
Chemotherapy
No 747 (86.8) 53 (70.7) <0.001
Yes 112 (13.0) 21 (28.0)
NA 2 (0.2) 1 (1.3)
ITC isolated tumour cell, BCS breast-conserving surgery, SNB sentinel node
biopsy, ALND axillary lymph node dissection, NA not available
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significant. The multivariable survival analyses were calculated
both with and without taking into account the given surgical and
adjuvant systemic treatments. The statistical analyses were done
using an IBM® SPSS® Statistics Version 20 software (SPSS Inc.,
Chicago, IL).
RESULTS
Association between presence of ITCs and clinicopathological
characteristics
There was no statistically significant difference between the pN0i
− groups and pN0i+ groups regarding patient age, tumour
histology, histological grade, the Ki-67 proliferation index, or
cancer steroid hormone receptor status. The patients with pN0i+
cancer had slightly larger median tumour diameter as compared
to patients with pN0i− disease (13 vs 12mm, respectively; P=
0.021). The patients with pN0i− cancer had a longer median
follow-up time than patients with pN0i+ cancer (9.5 vs 9 years,
respectively; P= 0.016).
ITCs and treatments given
The patients with ITCs in the SNs were generally treated more
extensively. Patients with pN0i+ cancer underwent more often
mastectomy and had an ALND, and they were treated more
1.0


























0 20 40 60
Follow-up time (months)






































0 20 40 60
Follow-up time (months)
80 100 120 140






P = 0.090 for log-rank test
P < 0.001 for log-rank test









































0 20 40 60
Follow-up time (months)
80 100 120 140
P = 0.652 for log-rank test












































0 20 40 60
Follow-up time (months)
80 100 120 140
a b
c d
Fig. 2 Distant disease-free survival (a), overall survival (b), breast cancer-specific survival (c), and locoregional recurrence-free survival (d) in
the study cohort
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frequently with systemic adjuvant therapies as compared to the
patients with pN0i− disease (Table 2).
Survival
Forty-seven (5.0%) patients were diagnosed with distant metas-
tases during the follow-up, 39 (4.5%) out of the 861 patients in the
pN0i− group, and 8 (10.7%) out of the 75 patients in the pN0i+
group. Ten-year distant disease-free survival was 95.3% in the
pN0i− group and 88.8% in the pN0i+ group (univariable Cox
regression hazard ratio [HR] 2.53, 95% CI 1.18–5.41; P= 0.017;
Fig. 2a, Table 3). In a multivariable Cox proportional hazards
regression analysis including all factors with prognostic influence
the presence of ITCs was an independent prognostic factor for
distant recurrence (HR 2.34, 95% CI 1.09–5.04; P= 0.029) together
with tumour Ki-67 proliferation index and diameter (Table 3).
During the follow-up 104 (11.1%) patients died, 92 (10.7%) out
of the 861 patients in the pN0i− group and 12 (16.0%) out of the
75 patients in the pN0i+ group. Ten-year overall survival was
89.2% in the pN0i− group and 83.8% in the pN0i+ group
(univariable Cox regression HR 1.67, 95% CI 0.92–3.06; P= 0.094;
Fig. 2b, Table 4). In a multivariable Cox regression analysis the
presence of ITCs was an independent predictor for overall survival
(HR 2.42, 95% CI 1.32–4.46; P= 0.005) together with age at
diagnosis and the Ki-67 proliferation index (Table 4).
Only 27 (26%) of the 104 deaths were considered to have
resulted from breast cancer (20 and 7 in the pN0i− and pN0i+
groups, respectively). The characteristics of patients with ITCs in
the SNs and who died of breast cancer during the follow-up are
provided in Supplementary Table 1. Ten-year breast cancer-
specific survival was as high as 97.6% in the pN0i− group and
90.1% in the pN0i+ group (univariable Cox regression HR 4.29,
95% CI 1.81–10.15; P= 0.001; Fig. 2c). In a multivariable Cox
proportional hazards regression analysis the presence of ITCs was
an independent prognostic factor for breast cancer-specific
survival (HR 4.13, 95% CI 1.75–9.77; P= 0.001) together with Ki-
67 proliferation index (HR 2.93, 95% CI 1.86–4.60; P < 0.001).
A locoregional recurrence was diagnosed in 50 (5.3%) patients
(47 [5.5%] and 3 [4.0%] in the pN0i− and pN0i+ groups,
respectively). Ten-year locoregional recurrence-free survival was
94.2% in the pN0i− group and 95.8% in the pN0i+ group (log-
rank P= 0.652; Fig. 2d).
The above survival analyses were performed without taking into
account the treatment-related variables (the types of surgery and
adjuvant treatments). The results remained largely unchanged
with respect to the prognostic importance of ITCs in multivariable
analyses for distant disease-free survival, overall survival, and
breast cancer-specific survival, when the type of surgery and the
adjuvant treatments given were included in the multivariable
models (Supplementary Tables 2, 3, and 4). Supplementary
information available at the British Journal of Cancer’s website.
DISCUSSION
We found that the presence of ITCs in the SNs was an
independent predictor of distant recurrence in this cohort of
patients with pT1 node-negative early breast cancer. The effect
seemed consistent regardless of the survival end point selected,
whether this was overall survival, breast cancer-specific survival, or
distant disease-free survival, but the ITCs did not predict
locoregional recurrence. Presence of ITCs was associated with
inferior survival outcomes both in univariable and multivariable
analyses, and regardless of whether the types of treatments
administered were included in the multivariable models or not. Of
note, the patients who had ITCs in the SNs had generally received
more systemic adjuvant treatments than those who did not have
ITCs, suggesting that the present estimates regarding the
Table 3. Univariable and multivariable survival analyses for distant
disease-free survival
Univariable analysis Multivariable analysis
HR 95% CI
for HR
P-value HR 95% CI
for HR
P-value
Age (years) 1.00 0.98–1.03 0.960
Tumour size
(mm)
1.13 1.06–1.21 0.001 1.08 1.01–1.16 0.033
N0i− vs N0i+ 2.53 1.18–5.41 0.017 2.34 1.09–5.04 0.029
Histological
grade





Lobular 0.55 0.21–1.40 0.208




ER status 3.23 1.70–6.12 <0.001 1.04 0.43–2.49 0.934
PR status 2.20 1.24–3.89 0.007 1.51 0.82–2.77 0.183
Ki-67 (MIB-1) 2.37 1.71–3.30 <0.001 2.16 1.54–3.04 <0.001
HER-2 (CISH) 3.46 1.59–7.56 0.002 1.76 0.76–4.08 0.415
FNAC fine needle aspiration cytology, CNB core needle biopsy, ER oestrogen
receptor, PR progesterone receptor, HER-2 (CISH) human epidermal growth
factor receptor 2 (chromogenic in situ hybridisation). Age, Ki-67 and the
histological grade were entered as continuous variables. Eighteen patients
had one or more missing values in the final steps of the analyses
Table 4. Univariable and multivariable survival analyses for overall
survival
Univariable analysis Multivariable analysis
HR 95% CI
for HR
P-value HR 95% CI
for HR
P-value
Age (years) 1.09 1.07–1.11 <0.001 1.09 1.08–1.11 <0.001
Tumour size
(mm)
1.06 1.01–1.11 0.011 1.03 0.98–1.08 0.299
N0i− vs N0i+ 1.67 0.92–3.06 0.094 2.42 1.32–4.46 0.005
Histological
grade





Lobular 0.94 0.56–1.58 0.803




ER status 1.49 0.89–2.53 0.158
PR status 0.94 0.61–1.45 0.777
Ki-67 (MIB-1) 1.32 1.04–1.67 0.024 1.41 1.11–1.79 0.005
HER-2 (CISH) 0.42 0.13–1.34 0.142
FNAC fine needle aspiration cytology, CNB core needle biopsy, ER oestrogen
receptor, PR progesterone receptor, HER-2 (CISH) human epidermal growth
factor receptor 2 (chromogenic in situ hybridisation). Age, Ki-67 and the
histological grade were entered as continuous variables. Nineteen patients
had one or more missing values in the final steps of the analyses
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prognostic significance of the ITCs may be conservative. Patients
who had no ITCs in the SNs had high 10-year distant disease-free
and breast cancer-specific survival rates.
Previous studies have yielded controversial conclusions regard-
ing the prognostic significance of ITCs in early breast cancer.
While some studies have considered ITCs to have prognostic
significance,10,17,19–21 others have not found such an associa-
tion.9,11–13,22–24 The controversial results may, in part, be explained
with the good short-term prognosis in pN0 breast cancer, and the
relatively small number of survival events. However, as we found
in the present and a previous study in this patient population,17
the number of survival events continues to increase with longer
follow-up.25 Thus it seems likely that in order to draw firm
conclusions on the prognostic importance of ITCs in the SNs long
follow-up times are needed.
The results suggest strongly that finding ITCs in the SNs is
associated with an increased risk of distant recurrence. The
mechanisms of cancer cell seeding that lead to distant recurrence
may be several, and the precise mechanisms may still be
incompletely understood. Nonetheless, extensive surgical treat-
ment of the axilla does not appear to result in survival benefits in
patients with ITCs in the SNs.9,26–29 Rather, the presence of ITC
might imply non-indolent biology of cancer, suggesting that
besides the SNs, the tumour may have seeded micrometastases
elsewhere in the body, which may sometimes manifest as overtly
metastatic disease only after a long latency period. If this
hypothesis is correct, aggressive local treatment of the axilla
may not benefit the patient, whereas adjuvant systemic treat-
ments might.
In node-negative breast cancer, the decision to administer
adjuvant systemic therapy has traditionally depended on tumour
characteristics such as size, grade, the proliferation index, the
hormone receptor status, and the HER-2 status. More recently,
biological subtypes, characterised with gene expression profiling,
or approximated with surrogate IHC profiles, have been suggested
as prognostic and predictive tools in the decision-making for
adjuvant systemic therapy.30 One suggested criterion for adjuvant
systemic therapy has been a more than 10% risk of recurrence
during a 10-year follow-up. In the current study population, seven
(9.3%) out of the 75 patients with pN0i+ cancer died of breast
cancer, and eight (10.7%) others had distant metastases, adding
up to a rate of 20% during a median follow-up time of 9.5 years.
The MIRROR study demonstrated reduced survival associated
with the presence on ITCs in the SNs in a series of 819 patients,
where 513 patients with pN0i+ cancer did not receive
systemic adjuvant therapy and 306 patients did. In this study
systemic adjuvant therapy improved survival of patients with
pN0i+ disease.15 Collectively, our data suggests that adjuvant
systemic therapy might be considered for patients with pN0i+
cancer.
The main limitation of the study is that the analyses were based
on a prospectively followed up cohort of patients, and not on a
clinical trial population with previously defined inclusion and
exclusion criteria and study procedures. The observational nature
of the study makes it challenging to assess the effect of the given
systemic therapies on prognosis. We limited the study to breast
cancer patients with a small (pT1) primary tumour. A small
proportion of the patients treated with a SNB have undetected
metastases in the axilla.31 Axillary dissection was carried out
substantially more frequently in the subset of patients with pN0i+
cancer than among those with pN0i− disease, and, therefore,
undetected macroscopic axillary metastases, if any, were present
more likely in the pN0i− group than in the pN0+ group, which
may have reduced the observed survival difference between the
groups.
Potential strengths of the study include a long follow-up time,
the population-based setting, and a relatively large sample size,
although the number of patients with ITCs in the SNs was
relatively small. The SNs were analysed centrally using a
standardised protocol, and the criteria for ITC detection remained
unaltered during the study. In another study from our institute,
the breast pathologists re-analysed the SNs histopathological
findings from a part of the present patient population, and found
only a very low rate of false-positive ITC findings.32 Most of the
patients with ITC-positive cancer underwent a completion ALND,
and patients with micrometastases or macrometastases in the
non-sentinel nodes could be excluded from the study. Therefore,
the ITC-positive patients in this study truly had pN0i+ cancer, a
patient population that may currently be difficult to identify, since
at present patients with ITC-positive cancer often do not undergo
ALND.
CONCLUSIONS
We conclude that the presence of ITCs in the SNs is associated
with an increased risk of distant recurrence in patients with
pT1N0M0 breast cancer. The current findings suggest that ITCs are
a biological tumour characteristic that is independently associated
with an increased risk for distant metastases, and may be
considered when evaluating the need for systemic adjuvant
therapy.
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